Results 191 to 200 of about 161,033 (215)

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety Up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

open access: yesArthritis &Rheumatology, EarlyView.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week, double‐blind, placebo‐controlled, phase 3 Program for Evaluation
Philip J. Mease   +20 more
wiley   +1 more source

Case report of an unusual allergic reaction to a routine skin prick test performed in an outpatient clinic: Diagnosis, management, and knowledge gaps. [PDF]

open access: yesMedicine (Baltimore)
Robles-Velasco K   +5 more
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Severity Grading System for Acute Allergic Reactions: A Multidisciplinary Delphi Study

Journal of Allergy and Clinical Immunology, 2021
Ronna Campbell   +2 more
exaly  

MRGPRX2 Mediates Immediate-Type Pseudo-Allergic Reactions Induced by Iodine-Containing Iohexol

Biomedicine and Pharmacotherapy, 2021
Bin Pan, Delu Che, Dongying Wu
exaly  

Characteristics of Food Allergic Reactions in United States Restaurants

Journal of Allergy and Clinical Immunology: in Practice, 2021
Thomas Casale   +2 more
exaly  

Allergic Reactions of the Lungs to Enzymes of Bacillus subtilis.

Lancet, The, 1969
Frederick E Hargreave   +2 more
exaly  

Home - About - Disclaimer - Privacy